Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7XBB

Crystal structure of PDE4D catalytic domain complexed with compound 23a

7XBB の概要
エントリーDOI10.2210/pdb7xbb/pdb
分子名称Isoform 3 of cAMP-specific 3',5'-cyclic phosphodiesterase 4D, ZINC ION, MAGNESIUM ION, ... (5 entities in total)
機能のキーワードpde4 inhibitor, hydrolase
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計116637.35
構造登録者
Huang, Y.-Y.,Luo, H.-B. (登録日: 2022-03-21, 公開日: 2022-07-06, 最終更新日: 2023-11-29)
主引用文献Zhou, F.,Huang, Y.,Liu, L.,Song, Z.,Hou, K.Q.,Yang, Y.,Luo, H.B.,Huang, Y.Y.,Xiong, X.F.
Structure-based optimization of Toddacoumalone as highly potent and selective PDE4 inhibitors with anti-inflammatory effects.
Biochem Pharmacol, 202:115123-115123, 2022
Cited by
PubMed Abstract: Phosphodiesterase-4 (PDE4) is an important drug target for inflammatory diseases. Previously, we identified a series of novel PDE4 inhibitors derived from the natural Toddacoumalone, among which the hit compound 2 with a naphthyridine scaffold showed moderate potency with the IC value of 400 nM. Based on the co-crystal structure of PDE4D-2, further structural optimizations and structure-activity relationship studies led to a highly potent PDE4 inhibitor 23a with the IC value of 0.25 nM and excellent selectivity profiles over other PDEs (>4000-fold). The co-crystal structure of PDE4D-23a elucidated that 23a has strong interactions with the M and Q pocket of PDE4D. Importantly, compound 23a significantly inhibits the release of inflammatory cytokines TNF-α and IL-6 in lipopolysaccharide-stimulated RAW264.7 cells. Thus, compound 23a with a naphthyridine scaffold is a promising PDE4 inhibitor for the treatment of inflammatory diseases.
PubMed: 35688178
DOI: 10.1016/j.bcp.2022.115123
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.10000900931 Å)
構造検証レポート
Validation report summary of 7xbb
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon